THER-06. GENOMIC AND IMMUNE CHARACTERIZATION OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES

INTRODUCTION: Approximately 50% of patients with metastatic triple negative breast cancer (TNBC) will develop brain metastases (BM). Routinely treated with radiotherapy and/or surgery, survival is generally less than one year. There are no approved systemic therapies to treat TNBC BM. We characteriz...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincent, Benjamin, Sambade, Maria, Chai, Shengjie, Siegel, Marni, Cuaboy, Luz, Holye, Alan, Parker, Joel, Perou, Charles, Anders, Carey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213186/
http://dx.doi.org/10.1093/noajnl/vdz014.049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213186/
http://dx.doi.org/10.1093/noajnl/vdz014.049

Ejemplares similares